Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Pre-clinical research

Diabetes drugs show promise in Alzheimer’s disease

Glucagon-like peptide-1 (GLP-1) receptor agonist drug used to treat type 2 diabetes could help against alzheimer's, study finds. In image, MRI scan of a human brain

Source: Shutterstock.com

Glucagon-like peptide-1 (GLP-1) receptor agonists — used to treat diabetes — might in future have a place in the management of Alzheimer’s disease

Type 2 diabetes is a risk factor for Alzheimer’s disease (AD), possibly mediated by impaired insulin signalling. This hypothesis is bolstered by new research showing that administration of glucagon-like peptide-1 (GLP-1) receptor agonists — which facilitate insulin signalling — has a neuroprotective effect in a mouse model of AD.

Paula McClean, from the University of Ulster, Northern Ireland, and Christian Hölscher, from Lancaster University, administered either liraglutide or lixisenatide to transgenic APP/PS1 mice. Both treatments led to significant improvements in how mice performed in an object recognition task. The drugs also improved long-term potentiation of synaptic transmission in the hippocampus, prevented a reduction in synapse numbers and reduced amyloid plaque load.

Liraglutide and lixisenatide “show promise as potential drug treatments of AD”, conclude the researchers in Neuropharmacology (online, November 2014)[1].

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067093

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.